Comparative Pharmacology
Head-to-head clinical analysis: KELNOR versus LOW OGESTREL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR versus LOW OGESTREL 28.
KELNOR vs LOW-OGESTREL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Norgestrel: ~45 hours (terminal). Ethinyl estradiol: ~13 hours (terminal). Steady-state achieved within 5-7 days.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Renal 50-60% as metabolites, fecal 40-50% via biliary elimination. Ethinyl estradiol undergoes enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive